Qin S, Bi F, Gu S, Bai Y, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol 2021 Jun 29:JCO2100163. doi: 10.1200/JCO.21.00163.
PMID: 34185551